User profiles for M. J. Anadkat
 | Milan AnadkatWashington University School of Medicine Verified email at wustl.edu Cited by 4144 |
[HTML][HTML] Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
ME Lacouture, MJ Anadkat, RJ Bensadoun… - Supportive Care in …, 2011 - Springer
Background Epidermal growth factor receptor inhibitors (EGFRI) produce various dermatologic
side effects in the majority of patients, and guidelines are crucial for the prevention and …
side effects in the majority of patients, and guidelines are crucial for the prevention and …
Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0
AP Chen, A Setser, MJ Anadkat, J Cotliar… - Journal of the American …, 2012 - Elsevier
Dermatologic adverse events to cancer therapies have become more prevalent and may to
lead to dose modifications or discontinuation of life-saving or prolonging treatments. This has …
lead to dose modifications or discontinuation of life-saving or prolonging treatments. This has …
[HTML][HTML] Trial of spesolimab for generalized pustular psoriasis
…, M Zheng, J Xu, H Turki, MJ Anadkat… - … England Journal of …, 2021 - Mass Medical Soc
Background Generalized pustular psoriasis (GPP) is a rare, life-threatening, inflammatory skin
disease characterized by widespread eruption of sterile pustules. Interleukin-36 signaling …
disease characterized by widespread eruption of sterile pustules. Interleukin-36 signaling …
Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines
ME Lacouture, V Sibaud, MJ Anadkat… - The …, 2021 - academic.oup.com
Identification of fibroblast growth factor receptor (FGFR) aberrations in cholangiocarcinoma
and bladder cancer led to development of selective FGFR inhibitors for these indications, …
and bladder cancer led to development of selective FGFR inhibitors for these indications, …
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
…, A Musiek, A Schaffer, MJ Anadkat… - Blood, The Journal …, 2018 - ashpublications.org
New therapies for patients with hematologic malignancies who relapse after allogeneic
hematopoietic cell transplantation (allo-HCT) are needed. Interleukin 15 (IL-15) is a cytokine that …
hematopoietic cell transplantation (allo-HCT) are needed. Interleukin 15 (IL-15) is a cytokine that …
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised …
Background Spesolimab is an anti-interleukin-36 receptor monoclonal antibody approved
to treat generalised pustular psoriasis (GPP) flares. We aimed to assess the efficacy and …
to treat generalised pustular psoriasis (GPP) flares. We aimed to assess the efficacy and …
Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines
…, M Abdelmalek, RL Ahmed, MJ Anadkat… - Transplant …, 2019 - Wiley Online Library
Skin cancer is the most common malignancy affecting solid organ transplant recipients ( SOTR
), and SOTR experience increased skin cancer‐associated morbidity and mortality. There …
), and SOTR experience increased skin cancer‐associated morbidity and mortality. There …
Life-threatening dermatologic adverse events in oncology
…, N Larsen, J Sorrell, DP West, MJ Anadkat… - Anti-cancer …, 2014 - journals.lww.com
… MJ Anadkat has received honoraria as a speaker and/or consultant for ImClone, Bristol
Myers Squibb, Eisai, Genentech, AstraZeneca, and Therakos. For the remaining authors there …
Myers Squibb, Eisai, Genentech, AstraZeneca, and Therakos. For the remaining authors there …
The effect of smoking and age on the response to first-line therapy of hidradenitis suppurativa: An institutional retrospective cohort study
G Denny, MJ Anadkat - Journal of the American Academy of Dermatology, 2017 - Elsevier
… Disclosure: Dr Anadkat has received honoraria as a speaker and/or consultant from
AstraZeneca, Bristol-Myers Squibb, Eisai, ImClone, and Therakos. He has also served as an …
AstraZeneca, Bristol-Myers Squibb, Eisai, ImClone, and Therakos. He has also served as an …
[HTML][HTML] Prevention and management of dermatologic adverse events associated with tumor treating fields in patients with glioblastoma
Importance: Tumor Treating Fields (TTFields) are an antineoplastic treatment approved for
treating newly diagnosed and recurrent glioblastoma, and mesothelioma. TTFields in …
treating newly diagnosed and recurrent glioblastoma, and mesothelioma. TTFields in …